X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (875) 875
index medicus (744) 744
hematology (717) 717
polycythemia-vera (632) 632
janus kinase 2 - genetics (619) 619
essential thrombocythemia (601) 601
mutation (562) 562
jak2 v617f mutation (489) 489
female (400) 400
male (395) 395
oncology (372) 372
myeloproliferative disorders (357) 357
middle aged (347) 347
tyrosine kinase jak2 (330) 330
jak2 (328) 328
aged (307) 307
adult (297) 297
myeloproliferative disorders - genetics (296) 296
myeloproliferative neoplasms (290) 290
myelofibrosis (272) 272
v617f mutation (262) 262
jak2 v617f (243) 243
polycythemia vera (220) 220
thrombosis (188) 188
genetic aspects (187) 187
thrombocythemia, essential - genetics (187) 187
chronic myeloproliferative disorders (185) 185
polycythemia vera - genetics (183) 183
aged, 80 and over (180) 180
diagnosis (171) 171
myeloid metaplasia (150) 150
risk factors (147) 147
disorders (146) 146
primary myelofibrosis (145) 145
jak2 mutation (143) 143
leukemia (142) 142
hemic and lymphatic diseases (141) 141
janus kinase 2 (125) 125
v617f (119) 119
janus kinase 2 - metabolism (116) 116
tumors (115) 115
animals (114) 114
alleles (110) 110
myeloproliferative disorders - diagnosis (109) 109
primary myelofibrosis - genetics (109) 109
research (107) 107
jak2v617f (105) 105
activating mutation (104) 104
adolescent (97) 97
pathology (96) 96
medicine & public health (95) 95
gene mutations (94) 94
mutation, missense (93) 93
polycythemia (92) 92
analysis (91) 91
prognosis (90) 90
hematology, oncology and palliative medicine (88) 88
jak2v617f mutation (88) 88
health aspects (86) 86
young adult (86) 86
allele burden (85) 85
phenotype (85) 85
abridged index medicus (84) 84
disease (84) 84
care and treatment (83) 83
mutation - genetics (83) 83
myeloproliferative neoplasm (82) 82
point mutation (82) 82
polymerase chain reaction (80) 80
acute myeloid-leukemia (79) 79
amino acid substitution (77) 77
risk (77) 77
chronic myeloid-leukemia (74) 74
myeloproliferative disorders - pathology (74) 74
neoplasms (74) 74
expression (72) 72
mice (72) 72
receptors, thrombopoietin - genetics (71) 71
retrospective studies (71) 71
world-health-organization (70) 70
medicine, general & internal (69) 69
thrombocythemia, essential - diagnosis (69) 69
polycythemia vera - pathology (68) 68
tyrosine kinase mutation (68) 68
peripheral vascular disease (65) 65
cancer (64) 64
idiopathic myelofibrosis (62) 62
dna mutational analysis (60) 60
prevalence (60) 60
thrombocythemia, essential - complications (60) 60
budd-chiari-syndrome (59) 59
classification (59) 59
risk-factors (59) 59
acute lymphoblastic-leukemia (58) 58
myeloproliferative disorders - enzymology (58) 58
bone marrow (57) 57
mpl (56) 56
janus kinase 2 - antagonists & inhibitors (55) 55
signal transduction (55) 55
thrombocytosis (55) 55
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1237) 1237
French (17) 17
German (11) 11
Russian (9) 9
Japanese (8) 8
Spanish (8) 8
Korean (7) 7
Polish (6) 6
Hungarian (5) 5
Turkish (3) 3
Czech (1) 1
Italian (1) 1
Romanian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 05/2009, Volume 360, Issue 22, pp. 2289 - 2301
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2013, Volume 369, Issue 25, pp. 2391 - 2405
Journal Article
Blood, ISSN 0006-4971, 04/2010, Volume 115, Issue 14, pp. 2891 - 2900
Journal Article
Blood, ISSN 0006-4971, 08/2007, Volume 110, Issue 3, pp. 840 - 846
Journal Article
Journal Article
BLOOD, ISSN 0006-4971, 04/2019, Volume 133, Issue 15, pp. 1677 - 1690
Over 80% of patients with myeloproliferative neoplasms (MPNs) harbor the acquired somatic JAK2(V617F) mutation. JAK inhibition is not curative and fails to... 
PROGENITOR CELLS | JAK2V617F EXPRESSION | POLYCYTHEMIA-VERA | MYELOPROLIFERATIVE NEOPLASM | DEPENDENT KINASE 6 | JAK2 V617F MUTATION | PROLIFERATION | MYELOID MALIGNANCIES | CELL-CYCLE PROGRESSION | HEMATOLOGY | HEMATOPOIETIC STEM
Journal Article
BLOOD, ISSN 0006-4971, 07/2007, Volume 110, Issue 1, pp. 375 - 379
To study the role of the JAK2-V617F mutation in leukemic transformation, we examined 27 patients with myeloproliferative disorders (MPDs) who transformed to... 
TRANSFORMATION | POLYCYTHEMIA-VERA | ACTIVATING MUTATION | JAK2(V617F) MUTATION | TYROSINE KINASE JAK2 | JAK2 V617F MUTATION | ACUTE MYELOID-LEUKEMIA |